DUBLIN , April 21, 2022 /PRNewswire/ -- The "Global Myopia and Presbyopia Treatment Market Size, Share & Trends Analysis Report by Myopia Treatment Type (Corrective, Surgical), Presbyopia Treatment Type (Prescription, Contact Lenses), Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global myopia and presbyopia treatment market size is expected to reach USD 28.0 billion by 2028, according to the report. The market is expected to expand at a CAGR of 7.9% from 2021 to 2028.

Growing research and development in the targeted disorders is expected to drive the market considerably over the forecast period. Moreover, the growing prevalence of myopia and high myopia is anticipated to fuel the market during the forecast period. Incidences of myopia in the developing countries of Asia Pacific , such as Japan , China , Singapore , and the Republic of Korea is growing steeply in recent years. According to Statista, myopia cases in the world are expected to rise by 28% in the next decade and by 30% for high myopia. The growing prevalence of myopia and presbyopia is an opportunity for industry players to introduce efficient treatment solutions. Among the developed nations, the U.S. is witnessing a significant boost in the incidence of myopia and presbyopia, especially in individuals over 42 years of age. The introduction of technologically advanced surgical options and high adoption rates in developed countries are expected to boost the market growth in upcoming years. Advanced diagnostic and surgical treatment solutions include LASIK, LASEK, and PRK. Integration of these techniques with artificial intelligence and robot-assisted surgical tools is expected to fuel the number of surgical procedures. The introduction of multifocal intraocular lenses and implantable contact lenses is expected to have a positive impact on the market growth. Myopia And Presbyopia Treatment Market Report Highlights

By myopia treatment type, the single prescription corrective lenses segment is expected to hold a significant revenue share of the market owing to the progression of myopia with age, thus requiring frequent changes of corrective lenses

The progressive multifocals segment is also expected to grow significantly over the forecast period owing to wide acceptance due to aesthetic advantages

The multifocal contact lenses for the correction of presbyopia held the largest revenue share in 2020 largely due to easy availability and effective outcomes

Key Topics Covered: Chapter 1. Methodology and Scope Chapter 2. Executive Summary Chapter 3. Myopia and Presbyopia Treatment Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Penetration & Growth Prospect Mapping 3.3. Industry Value Chain Analysis 3.3.1. Reimbursement framework 3.4. Market Dynamics 3.4.1. Market driver analysis 3.4.2. Market restraint analysis 3.4.3. Industry challenges 3.5. Myopia and Presbyopia Treatment Market Analysis Tools 3.5.1. Industry Analysis - Porter's 3.5.1.1. Supplier power 3.5.1.2. Buyer power 3.5.1.3. Substitution threat 3.5.1.4. Threat of new entrant 3.5.1.5. Competitive rivalry 3.5.2. PESTEL Analysis 3.5.2.1. Political landscape 3.5.2.2. Technological landscape 3.5.2.3. Economic landscape 3.5.3. Major Deals & Strategic Alliances Analysis 3.5.4. Market Entry Strategies Chapter 4. Myopia Treatment Type Estimates & Trend Analysis 4.1. Definitions and Scope 4.1.1. Corrective 4.1.1.1. Prescription Lenses 4.1.1.1.1. Single 4.1.1.1.2. Bifocal 4.1.1.1.3. Trifocal 4.1.1.1.4. Others 4.1.1.2. Contact Lenses 4.1.2. Surgical 4.1.3. Drugs 4.2. Myopia Treatment Type Market Share, 2020 and 2028 4.3. Segment Dashboard 4.4. Global Myopia and Presbyopia Treatment Market by Myopia Treatment Type Outlook 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2028 for the following 4.5.1. Corrective 4.5.1.1. Prescription Lenses 4.5.1.1.1. Single 4.5.1.1.2. Bifocal 4.5.1.1.3. Trifocal 4.5.1.1.4. Others 4.5.1.2. Contact Lenses 4.5.2. Surgical 4.5.3. Drugs Chapter 5. Presbyopia Treatment Type Estimates & Trend Analysis 5.1. Definitions and Scope 5.1.1. Prescription Lenses 5.1.1.1. Reading Glasses 5.1.1.2. Bifocals 5.1.1.3. Trifocals 5.1.1.4. Progressive Multifocals 5.1.1.5. Office Progressives 5.1.2. Contact Lenses 5.1.2.1. Bifocal 5.1.2.2. Multifocal 5.1.2.3. Monovison 5.1.2.4. Modified Monovision 5.1.3. Intraocular Lenses 5.1.4. Refractive Surgery 5.2. Presbyopia Treatment Type Market Share, 2020 and 2028 5.3. Segment Dashboard 5.4. Global Myopia and Presbyopia Treatment Market by Presbyopia Treatment Type Outlook 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2028 for the following 5.5.1. Prescription Lenses 5.5.1.1. Reading Glasses 5.5.1.2. Bifocals 5.5.1.3. Trifocals 5.5.1.4. Progressive Multifocals 5.5.1.5. Office Progressives 5.5.2. Contact Lenses 5.5.2.1. Bifocal 5.5.2.2. Multifocal 5.5.2.3. Monovison 5.5.2.4. Modified Monovision 5.5.3. Intraocular Lenses 5.5.4. Refractive Surgery Chapter 6. Myopia and Presbyopia Treatment: Regional Estimates & Trend Analysis Chapter 7. Competitive Landscape 7.1. Recent Developments & Impact Analysis, By Key Market Participants 7.2. Company/Competition Categorization 7.2.1. Innovators 7.3. Vendor Landscape 7.3.1. List of key distributors and channel partners 7.3.2. Key customers 7.3.3. Key company market share analysis, 2018 7.3.4. Zeimer Ophthalmic Systems AG 7.3.4.1. Company Overview 7.3.4.2. Financial performance 7.3.4.3. Product Benchmarking 7.3.4.4. Strategic Initiatives 7.3.5. NIDEK CO. LTD. 7.3.5.1. Company Overview 7.3.5.2. Financial performance 7.3.5.3. Product Benchmarking 7.3.5.4. Strategic Initiatives 7.3.6. Johnson & Johnson Vision 7.3.6.1. Company Overview 7.3.6.2. Financial performance 7.3.6.3. Product Benchmarking 7.3.6.4. Strategic Initiatives 7.3.7. ZEISS International 7.3.7.1. Company Overview 7.3.7.2. Financial performance 7.3.7.3. Product Benchmarking 7.3.7.4. Strategic Initiatives 7.3.8. ALCON VISION LLC 7.3.8.1. Company Overview 7.3.8.2. Financial performance 7.3.8.3. Product Benchmarking 7.3.8.4. Strategic Initiatives 7.3.9. Bausch & Lomb Incorporated 7.3.9.1. Company Overview 7.3.9.2. Financial performance 7.3.9.3. Product Benchmarking 7.3.9.4. Strategic Initiatives 7.3.10 . Haag-Streit UK 7.3.10.1. Company Overview 7.3.10.2. Financial performance 7.3.10.3. Product Benchmarking 7.3.10.4. Strategic Initiatives 7.3.11 . Topcon Corporation 7.3.11.1. Company Overview 7.3.11.2. Financial performance 7.3.11.3. Product Benchmarking 7.3.11.4. Strategic Initiatives 7.3.12 . Essilor Ltd. 7.3.12.1. Company Overview 7.3.12.2. Financial performance 7.3.12.3. Product Benchmarking 7.3.12.4. Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/nztpuz

Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/insights-on-the-myopia-and-presbyopia-treatment-global-market-to-2028---by-myopia-treatment-type-presbyopia-treatment-type-and-region-301529968.html

Micron could be the cheapest tech stock in the market, based on its price/earnings ratio. Western Digital isn’t far behind.

Entering the final day of trading this week, the stock of Chinese electric vehicle maker Nio (NYSE: NIO) had been down more than 12% just this week, and more than 25% over the past month. After rising more than 9% Friday morning, Nio American depositary shares (ADSs) were still up 7.1% as of 10:50 a.m. ET. There are fears the U.S.-listed ADSs could be delisted as the company joined a growing list of Chinese names that will be required to provide proof of meeting U.S. accounting and audit standards for three straight years.

Feel poorer after the S&P 500's sell-off? Just know it could be worse. Much worse. Investors who piled in some $40 billion firms found out.

(Bloomberg) -- An investment firm for the Walton family ramped up its position in a U.S. municipal bond fund and added a sizable stake in Japanese equities, while also betting on small-cap stocks and Coinbase Global Inc. before tumultuous declines. Most Read from BloombergElon Musk Sows Doubt Over His $44 Billion Twitter TakeoverSony PlayStation Staff Fume Over CEO’s Abortion CommentsApple Testing iPhones That Ditch Lightning Ports in Favor of USB-CElon Musk Trolls TwitterUkraine Latest: US Sena

A cryptocurrency crash has already wiped out $600 billion in digital asset market value over the past week. With the declines in crypto outpacing those in stocks, Bitcoin may actually be a bellwether for capitulation among investors—that point when the market can really find a bottom, according to analyst Barry Bannister at Stifel. “We monitor several factors which we believe will mark the capitulatory low for stocks,” Bannister said in a Wednesday note.

Billionaire Warren Buffet is one of two people in the top ten richest people in the world who has seen his net worth rise since January, according to the Bloomberg Billionaires Index. The CEO of Berkshire Hathaway ( (BRK.A) - Get Berkshire Hathaway Inc. Class A Report, is ranked number five on the index, which is a daily ranking of the world's richest people. The only other billionaire in the top 10 of the Bloomberg list is Gautam Adani, an Indian infrastructure magnate that owns real estate, commodities and power generation and transmission, whose total net worth is $102 billion and his year-to-date performance is a profit of $25.5 billion.

Nvidia (NASDAQ: NVDA) shareholders were in for a pleasant surprise Friday as the semiconductor maker made significant gains. As of 1:05 p.m. ET, Nvidia's share price had surged by  9.8% as investors became more bullish about the market in general. The tech-heavy Nasdaq Composite was up by nearly 4% at that point in the session.

Big downturns are part of the investing game. No one knows where the bottom is, but here’s where to find good deals in quality stocks.

In this article, we will discuss the 12 best energy stocks for 2022. If you want to skip our detailed analysis of the energy sector which highlights key trends and major players, you can go directly to 5 Best Energy Stocks for 2022. The energy sector has been the biggest contributor to skyrocketing inflation in […]

(Bloomberg) -- The week is ending on a higher note for Big Tech on hopes a relentless selloff may be nearing exhaustion. But Friday’s rally can’t completely wipe out a sobering signal from Apple Inc. shares. Most Read from BloombergElon Musk Sows Doubt Over His $44 Billion Twitter TakeoverSony PlayStation Staff Fume Over CEO’s Abortion CommentsApple Testing iPhones That Ditch Lightning Ports in Favor of USB-CElon Musk Trolls TwitterUkraine Latest: US Senator Delays Aid Vote; Russia Eyes BorderAf

A rally attempt is underway. Get ready, get set, but don't go just yet. Chevron, Broadcom, Tesla and Twitter are among stocks to watch.

Our call of the day from Thomas Kee Jr. is pounding the table over the importance of volatility, but says investors need to not just fear the lows, but embrace the highs.

Investors are studying an array of indicators for clues on how much further a brutal slide in U.S. stocks could run, with some signs suggesting the tumble in equities may not be over. The S&P 500 extended its decline to nearly 20% from January’s record peak on Thursday before an end-of-week bounce, approaching the cusp of a bear market amid concerns that persistently high inflation will prompt more aggressive Federal Reserve interest rate increases that could undermine the economy. Declines have been even steeper in the tech-heavy Nasdaq Composite, which is down 24.5% year-to-date.

Shares of Boeing (NYSE: BA) joined the rally on Friday morning, trading up more than 6% at one point, only to give up most of those gains as they day went on. Investors got a reminder of the challenges that face Boeing's commercial division, taking the wind out of the shares. It's been a tough run for Boeing, with shares down by more than 60% since the start of 2020.

(Bloomberg) -- Moderna Inc. said it acted immediately to remove Jorge Gomez as chief financial officer earlier this week after it learned of an investigation related to the handling of incentives at his former company. Most Read from BloombergElon Musk Sows Doubt Over His $44 Billion Twitter TakeoverSony PlayStation Staff Fume Over CEO’s Abortion CommentsApple Testing iPhones That Ditch Lightning Ports in Favor of USB-CElon Musk Trolls TwitterUkraine Latest: US Senator Delays Aid Vote; Russia Ey

The end of the U.S. stock market’s correction is looking a lot closer. It’s encouraging, from a contrarian perspective, that the market timer community in recent days has become extremely pessimistic — as pessimistic, in fact, as it has been at prior market bottoms.

(Bloomberg) -- California Governor Gavin Newsom said Friday that his state has a record $97.5 billion operating surplus, as high tax rates on its wealthiest residents mean he has more cash to fund liberal priorities such as education and health care.Most Read from BloombergElon Musk Sows Doubt Over His $44 Billion Twitter TakeoverSony PlayStation Staff Fume Over CEO’s Abortion CommentsApple Testing iPhones That Ditch Lightning Ports in Favor of USB-CElon Musk Trolls TwitterUkraine Latest: US Sen

The stock market presents a somewhat confusing picture for now. The main indexes are all steeply down for the year so far – with losses of 16% on the S&P 500 and 25% on the NASDAQ. Drops of this magnitude come with a caveat, however: it’s inevitable that some fundamentally sound stocks are seeing drops in share price just due to the overall market’s downward trend. Indeed, Wall Street’s analysts are seeing plenty, in their words, attractive entry points -- beaten-down stocks that are primed for

The S&P 500 still has plenty of room to fall, if history is any guide

The departing executives said he was asked to leave by the CEO, who "wants to take the team in a different direction."